KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Non-Current Deffered Revenue (2018 - 2024)

BioNTech SE (BNTX) posted Non-Current Deffered Revenue of $195.6 million for Q4 2024, down 54.39% on a QoQ basis from $428.8 million in Q4 2023, and down 54.39% year-over-year from $428.8 million in Q1 2024.

BioNTech SE (BNTX) has 7 years of Non-Current Deffered Revenue data on file, last reported at $195.6 million in Q4 2024.

  • In Q4 2024, Non-Current Deffered Revenue fell 54.39% year-over-year to $195.6 million; the TTM figure through Dec 2024 stood at $195.6 million (down 54.39% YoY), while the FY2024 annual figure was $195.6 million, down 54.39% from the prior year.
  • Non-Current Deffered Revenue fell to $195.6 million in Q4 2024, from $428.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $428.8 million in Q4 2023 and bottomed at $10.3 million in Q4 2021.
  • A 5-year average of $153.9 million and a median of $85.7 million in 2020 frame the typical range for Non-Current Deffered Revenue.
  • Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue plunged 87.99% — and 2023, when it surged 768.29%.
  • Year by year, Non-Current Deffered Revenue stood at $85.7 million in 2020, then plunged by 87.99% to $10.3 million in 2021, then jumped by 379.62% to $49.4 million in 2022, then surged by 768.29% to $428.8 million in 2023, then tumbled by 54.39% to $195.6 million in 2024.
  • The last three Non-Current Deffered Revenue figures came in at $195.6 million (Q4 2024), $428.8 million (Q4 2023), and $49.4 million (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 225.10 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 BioNTech SE 27.66 Bn 7.53 Bn 668.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 195.55 Mn
Dec 31, 2023 428.76 Mn
Dec 31, 2022 49.38 Mn
Dec 31, 2021 10.30 Mn
Dec 31, 2020 85.73 Mn
Dec 31, 2019 107.49 Mn
Dec 31, 2018 234.72 Mn